For US Healthcare Professionals
Prescribing Information
POSLUMA logo
HEAD-TO-HEAD
POSLUMA vs 18F-DCFPyL in patients with BCR and very low PSA levels (≤0.5 ng/mL)

POSLUMA outperformed 18F-DCFPyL

icon for head-to-head study

A prospective, multicenter, intrapatient, head-to-head comparator study of patients with suspected biochemical recurrence of prostate cancer who received scans with 18F-DCFPyL and POSLUMA1

Study design
Urinary bladder activity
Detection rate
Study design
Urinary bladder activity
Detection rate

STUDY DESIGN

POSLUMA vs 18F-DCFPyL: Evaluating urinary bladder activity and detection rates

Organization icon

Initial enrollment

67 patients enrolled with BCR and PSA levels ≤0.5 ng/mL1

arrow icons
Organization icon

PSMA PET administration

18F-DCFPyL1

At least 24 hours, but no more than 10 days between scans1

arrow icons
Organization icon

Second PSMA PET administration

POSLUMA PET1

arrow icons
Organization icon

Evaluation

55 evaluable patients with both PSMA PET scans1

ENDPOINTS

Primary endpoint1

Difference in urinary bladder SUVmean as determined using quantification software

  • The difference in urinary bladder SUVmean will be calculated for each patient as: 18F-DCFPyLSUVmean – POSLUMA SUVmean

Secondary endpoints1

Detection rate analyses including patient level and subgroups, PSA level, prostate bed and related subregions, and pelvic lymph nodes

  • Determined by 2 blinded readers, with a third independent reader resolving disagreements
  • Scans were not matched by patient for comparison

URINARY BLADDER ACTIVITY

Median urinary bladder activity for 18F-DCFPyL was statistically significantly higher than POSLUMA1

3x higher graphic

bladder SUVmean for 18F-DCFPyL than for POSLUMA as measured by quantification software1

The difference is obvious: POSLUMA precision imaging facilitates quick, detailed interpretation

Image of POSLUMA and 18F-DCFPyL scans

DETECTION AT VERY LOW PSA LEVELS

POSLUMA had higher detection rates at very low PSA levels compared to 18F-DCFPyL1

Secondary endpoint: Patient-level detection rate (n=55)

Graphic showing 45% patient-level detection rate
Graphic showing 45% patient-level detection rate

Mean baseline PSA was 0.28 ng/mL (SD, 0.11).

How can POSLUMA elevate your detection and clinical decision-making?

Next Up

Established Safety and Tolerability With POSLUMA

Explore related content

Map iconFind an imaging center
Form iconStay informed

BCR=biochemical recurrence; IQR=interquartile range; SUVmean=mean standardized uptake value.

References: 1. Nordquist LT, Andrews JR, Kuo PH, et al. An intra-patient contemporaneous comparison of 18F-piflufolastat and 18F-flotufolastat urinary radioactivity and pelvic region detection rates in men with low PSA biochemical recurrence of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2026. doi:10.1007/s00259-025-07732-y